On September 13, 2019, the U.S. Food and Drug Administration began investigating the drug Ranitidine (brand name Zantac) after a Citizen Petition was issued by Valisure, an online specialty pharmacy that detected extraordinary levels of NDMA in Ranitidine. Following this discovery, numerous manufacturers have recalled their Zantac and Ranitidine products.
If you or a loved one was a regular user of Zantac and has been diagnosed with a digestive tract cancer, please contact the law offices of Sullivan, Papain, Block, McGrath & Cannavo, P.C. today to discuss your case. You may be eligible for significant compensation for your injuries.
At Sullivan, Papain, Block, McGrath & Cannavo, P.C., our product liability attorneys are dedicated to seeking justice for you and obtaining the maximum possible compensation for your injuries.
We are dedicated to holding pharmaceutical companies accountable for any negligent actions that may have caused profound harm to you and your loved ones.
Zantac is a popular over-the-counter drug currently manufactured by pharmaceutical company Sanofi. The active drug in Zantac, ranitidine, is an antacid commonly used to treat heartburn and other more serious health conditions such as acid reflux and gastroesophageal reflux disease (GERD).
In 2019, a third-party pharmacy tested samples of Zantac and found exceedingly high levels of N-nitrosodimethylamine (NDMA) in the drug. NDMA is a carcinogenic chemical that can be extremely potent in high levels of consumption. In fact, scientists and researchers often use NDMA in live animal cancer studies to induce tumors in live mice. While the FDA’s “acceptable” daily intake for NDMA is 96 ng, Valisure’s testing demonstrated the presence of approximately 3,000,000 ng of NDMA in a single ranitidine tablet.
Not only did the recent Zantac testing yield alarming results, but it suggested that the ranitidine molecule itself, can be broken down into NDMA. Although the manufacturers claim that this could only happen if Zantac were exposed to extremely high heat, further testing has found abnormally high trace amounts of NDMA in packaged samples of Zantac – demonstrating the instability of the drug.
On September 23rd, 2019, the FDA announced the first voluntary recall of drugs containing ranitidine. Since then, there have been 14 additional recalls from notable pharmaceutical manufacturers, including:
Those who have consistently consumed Zantac for an extended period of time, are likely at an increased risk for forms of cancer in the digestive tract due to the excessive amounts of NDMA consumption. This includes:
Pharmaceutical companies have a duty to produce safe drugs and to warn the public of health risks associated with their drugs. Zantac has been manufactured by a number of different pharmaceutical companies, including GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Sanofi-AS, any of which may be responsible for cancers caused by Zantac, depending on when Zantac was consumed.
At Sullivan, Papain, Block, McGrath & Cannavo, P.C., we have the resources, experience, and knowledge of product liability cases to help you receive compensation for any serious illnesses contracted as a result of regular Zantac consumption.
We are committed to securing the maximum possible compensation for your needs, so that you can have a chance at full recovery, and we can hold any accountable parties responsible for their negligent actions.
If you or a loved one has contracted a form of cancer due to regular Zantac or ranitidine use, please contact our New York City product liability attorneys today. We are here to help you seek justice for the irresponsible actions of several pharmaceutical companies. Schedule a free confidential consultation with us to see how we can help.